Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04581096
Other study ID # COVID19-MAPA
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 2, 2020
Est. completion date June 15, 2021

Study information

Verified date November 2021
Source Hospital General Universitario de Valencia
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

One of the major problems in suppressing the spreading of an epidemic resides in understanding and monitoring its propagation patterns, and in evaluating how these are modified by enforced policies. The standard solution requires detailed information at the microscopic scales, e.g. how infected people have moved and whom they came in contact with, which is hardly ever available. The researchers propose a novel approach to the study of the propagation of COVID-19, in which a proxy of this information is derived at macroscopic scales. This will be based on two ingredients: the spatiotemporal study in shiny with mathematical models with aggregated or non aggregated data and the reconstruction of functional networks of spreading patterns, and the development of a supporting software.


Recruitment information / eligibility

Status Completed
Enrollment 2646
Est. completion date June 15, 2021
Est. primary completion date February 15, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - positive test (PCR or serology) for SARS-CoV-2 - outpatient follow-up Exclusion Criteria: - hospitalisation in ward or ICU

Study Design


Intervention

Other:
no intervention
just descriptive analysis of clinical data

Locations

Country Name City State
Spain CHGUV Valencia
Spain CHGUV Valencia

Sponsors (2)

Lead Sponsor Collaborator
Hospital General Universitario de Valencia University of Valencia

Country where clinical trial is conducted

Spain, 

References & Publications (2)

Briz-Redón Á, Iftimi A, Correcher JF, De Andrés J, Lozano M, Romero-García C. A comparison of multiple neighborhood matrix specifications for spatio-temporal model fitting: a case study on COVID-19 data. Stoch Environ Res Risk Assess. 2021 Aug 18:1-12. doi: 10.1007/s00477-021-02077-y. [Epub ahead of print] — View Citation

Romero García C, Iftimi A, Briz-Redón Á, Zanin M, Otero M, Ballester M, de Andrés J, Landoni G, de Las Marinas D, Catalá Bauset JC, Mandingorra J, Conca J, Correcher J, Ferrer C, Lozano M. Trends in Incidence and Transmission Patterns of COVID-19 in Valencia, Spain. JAMA Netw Open. 2021 Jun 1;4(6):e2113818. doi: 10.1001/jamanetworkopen.2021.13818. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary spatiotemporal spread spatiotemporal spread of COVID-19 patient in our hospital February 1, 2020 to September 30, 2020
Secondary classification score risk classification score of each patients with clinical and analytical variables February 1, 2020 to September 30, 2020
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3